New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
07:21 EDTAGN, VRXValeant recent weakness a buying opportunity, says JPMorgan
JPMorgan recommends using the recent pullback in shares of Valeant (VRX) as a buying opportunity. After meeting with management, the firm has increased confidence in the company's ability to show accelerating top-line growth in the second half of 2014. It sees "compelling value" in Valeant shares regardless of the Allergan (AGN) outcome and keeps an Overweight rating on the stock with a $180 price target.
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
May 20, 2015
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information
May 15, 2015
17:15 EDTVRXPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
17:08 EDTVRXSoros Fund gives quarterly update on stakes
Subscribe for More Information
17:03 EDTVRXPershing Square gives quarterly update on stakes
Subscribe for More Information
10:55 EDTVRXJANA Partners gives quarterly update on stakes
Subscribe for More Information
10:29 EDTAGNAmerican Urological Association to hold an annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use